World Journal of Gastrointestinal Pharmacology and Therapeutics

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62]
URL:	https://www.wjgnet.com/2150-5349/full/v3/i4/62.htm

(0) (0) (0) (5104) (34)

Number	Citing Articles
1	E. M. Ledeneva, A. L. Vertkin, Yu. V. Sediakina, N. A. Burakova, M. M. Shamuilova, S. S. Kurdjieva. Management of patients with liver cirrhosis at outpatient stage: How not to miss it?. Medical alphabet 2023; (35) doi: 10.33667/2078-5631-2022-35-14-18
2	Hao Wu, Yu-Tong Wu, Ying Li. Management of hepatic encephalopathy following transjugular intrahepatic portosystemic shunts: Current strategies and future directions. World Journal of Gastroenterology 2025; 31(15): 103512 doi: 10.3748/wjg.v31.i15.103512 Abstract(453) \| Core Tip(477) \| Full Article(HTML)(3681) \| Full Article (PDF)-2498K(269) \| Full Article with Cover (PDF)-2788K(248) \| Full Article (XML)-331K(105) \| Audio-1276K(31) \| Peer-Review Report-219K(83) \| Answering Reviewers-64K(110) \| Times Cited (3) \| Total Visits (4722) \| Open
3	Abhishek Basappanamalige Lokesh Reddy, Sabeena Kizhedath, Bindhu Vasudevan. COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY. Journal of Evolution of Medical and Dental Sciences 2017; 6(74) doi: 10.14260/Jemds/2017/1153
4	Marcos F. Ocaña-Sánchez, Gabriel A. Soto-Ojeda, Yolanda Cocotle-Ronzón, Cesar Soria-Fregozo, Alberto Sánchez-Medina, Rosa V. García-Rodríguez, Juan F. Rodríguez-Landa, Erick J. Corro-Méndez, Minerva Hernández-Lozano. Flaxseed Oil (Linum usitatissimum) Prevents Cognitive and Motor Damage in Rats with Hyperammonemia. Nutrients 2023; 15(21) doi: 10.3390/nu15214550
5	Leen Z. Hasan, George Y. Wu. Novel Agents in the Management of Hepatic Encephalopathy: A Review. Journal of Clinical and Translational Hepatology 2021; 0(000) doi: 10.14218/JCTH.2021.00102
6	Yi-Kuan Tseng, Ken-Ning Hsu. Study design for a three-arm equivalence clinical trial with binomially distributed outcomes. Journal of Biopharmaceutical Statistics 2021; 31(6) doi: 10.1080/10543406.2021.1968891
7	Lorenzo Ridola, Angelo Zullo, Cesare Hassan. Rifaximin as treatment for hepatic encephalopathy: Some considerations. Saudi Journal of Gastroenterology 2013; 19(1) doi: 10.4103/1319-3767.105930
8	Halina White. Gastrointestinal Disorders and the Nervous System. Continuum 2020; 26(3) doi: 10.1212/CON.0000000000000871
9	Fei Yu, Shuming Ji, Zaiyun Xiao, Xinyi Zhao, Jie Zhong. Sample size calculation in three-arm equivalence trials including a placebo for binary clinical endpoints. iScience 2026; 29(2) doi: 10.1016/j.isci.2026.114686
10	Antonio Gasbarrini, Maurizio Pompili, Maria Assunta Zocco, Loris Lopetuso, Francesca D’Aversa, Silvia Pecere, Viviana Gerardi, Francesca Romana Ponziani. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology 2015; 21(43): 12322-12333 doi: 10.3748/wjg.v21.i43.12322 Abstract(1685) \| Core Tip(1551) \| Full Article(HTML)(11922) \| Full Article (PDF)-955K(1114) \| Full Article (Word)-420K(422) \| Peer-Review Report-129K(464) \| Answering Reviewers-148K(405) \| Times Cited (73) \| Total Visits (14645) \| Open
11	Hector Ferral, Elisa Gomez-Reyes, Claus J Fimmel. Post–Transjugular Intrahepatic Portosystemic Shunt Follow-Up and Management in the VIATORR Era. Techniques in Vascular and Interventional Radiology 2016; 19(1) doi: 10.1053/j.tvir.2016.01.009
12	Roberto Lorenzetti, Cosimo Prantera. Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. Clinical Investigation 2013; 3(12) doi: 10.4155/cli.13.96
13	Daniel Paulson, Mona Shah, Lisa Renee Miller-Matero, Anne Eshelman, Marwan Abouljoud. Cognition Predicts Quality of Life Among Patients With End-Stage Liver Disease. Psychosomatics 2016; 57(5) doi: 10.1016/j.psym.2016.03.006
14	C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Eficacia de la rifaximina en los diferentes escenarios clínicos de la encefalopatía hepática. Revista de Gastroenterología de México 2020; 85(1) doi: 10.1016/j.rgmx.2019.09.001
15	Asmaa N. Mohammad, Mahmoud K. Elsamman, Amr M. Zaghloul, Hameda H. Mohamed, Walaa I. Mohammed. Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis. The Egyptian Journal of Internal Medicine 2018; 30(3) doi: 10.4103/ejim.ejim_19_18
16	Ameet Dhar, Benjamin H Mullish, Pinelopi Manousou, Roberta Forlano, Rooshi Nathwani, David Kockerling. Current and future pharmacological therapies for managing cirrhosis and its complications. World Journal of Gastroenterology 2019; 25(8): 888-908 doi: 10.3748/wjg.v25.i8.888 Abstract(1595) \| Core Tip(2010) \| Full Article(HTML)(14250) \| Full Article (PDF)-1193K(2227) \| Full Article (Word)-132K(400) \| Audio-2320K(53) \| Peer-Review Report-349K(350) \| Answering Reviewers-202K(362) \| Times Cited (43) \| Total Visits (18719) \| Open
17	Natalia Szóstak, Marek Figlerowicz, Anna Philips. The emerging role of the gut mycobiome in liver diseases. Gut Microbes 2023; 15(1) doi: 10.1080/19490976.2023.2211922
18	C.E. Coronel-Castillo, J. Contreras-Carmona, A.C. Frati-Munari, M. Uribe, N. Méndez-Sánchez. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020; 85(1) doi: 10.1016/j.rgmxen.2019.09.003
19	Georgia Tsakiridou, Antigoni Maria Papanastasiou, Panagiotis Efentakis, Maria Faidra Galini Angelerou, Lida Kalantzi. Challenges in the Investigation of Therapeutic Equivalence of Locally Applied/Locally Acting Drugs in the Gastrointestinal Tract: The Rifaximin Case. Pharmaceutics 2025; 17(7) doi: 10.3390/pharmaceutics17070839
20	E. Bouza, L. Alcalá, M. Marín, M. Valerio, E. Reigadas, P. Muñoz, M. González-Del Vecchio, V. de Egea. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. European Journal of Clinical Microbiology & Infectious Diseases 2017; 36(10) doi: 10.1007/s10096-017-2991-y
21	Pallab Ray, Shreya Singh, Swati Gupta. Topical Antimicrobial Therapy: Current Status and Challenges. Indian Journal of Medical Microbiology 2019; 37(3) doi: 10.4103/ijmm.IJMM_19_443
22	R. Ennaifer, N. Elleuch, M. Cheikh, H. Romdhane, H. Ben Nejma, N. Bel Hadj. La rifaximine : une nouvelle alternative dans la prévention des infections bactériennes chez le cirrhotique ?. Journal Africain d'Hépato-Gastroentérologie 2015; 9(3) doi: 10.1007/s12157-015-0606-8
23	Charlotte Skinner, Alex J. Thompson, Mark R. Thursz, Julian R. Marchesi, Nikhil Vergis. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820942616
24	Angelo Zullo, Lorenzo Ridola, Cesare Hassan. Rifaximin Therapy and Clostridium difficile Infection. Journal of Clinical Gastroenterology 2013; 47(8) doi: 10.1097/MCG.0b013e31828bea4b
25	Amber Ruest. Gastrointestinal Emergencies. 2019; doi: 10.1007/978-3-319-98343-1_73
26	Jordi Sanchez-Delgado, Mireia Miquel. Papel de la rifaximina en el tratamiento de la encefalopatía hepática. Gastroenterología y Hepatología 2016; 39(4) doi: 10.1016/j.gastrohep.2015.08.003
27	Shahabuddin Rind, Bashir Ahmed Chandio, Khalil Ahmed Sanghro, Yar Muhammad Tunio, Altaf Ahmed shaikh, Abdul Rashid dayo. Outcome of patients taking rifaxamine Vs lactose in patients with hepatic encephalopathy presenting at tertiary care hospital sukkur. Cuestiones de Fisioterapia 2024; 53(03) doi: 10.48047/yxbgmq37
28	Yuval Ishay, Yotam Kolben, Asa Kessler, Yaron Ilan. Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. American Journal of Physiology-Gastrointestinal and Liver Physiology 2021; 321(4) doi: 10.1152/ajpgi.00186.2021
29	Khadija A. M. Glal, Sherief M. Abd‐Elsalam, Tarek M. Mostafa. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double‐blind controlled trial. Journal of Hepato-Biliary-Pancreatic Sciences 2021; 28(10) doi: 10.1002/jhbp.947
30	Axel Holstege. Hepatische Enzephalopathie Teil 2: Therapie. Gastroenterologie up2date 2023; 19(04) doi: 10.1055/a-2039-9694
31	Jordi Sanchez-Delgado, Mireia Miquel. Role of rifaximin in the treatment of hepatic encephalopathy. Gastroenterología y Hepatología (English Edition) 2016; 39(4) doi: 10.1016/j.gastre.2016.03.006
32	T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case study. Meditsinskiy sovet = Medical Council 2023; (8) doi: 10.21518/ms2023-129
33	Motoh Iwasa, Yoshiyuki Takei. Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia. Hepatology Research 2015; 45(12) doi: 10.1111/hepr.12495